53P Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
P-MUC1C-ALLO1 cells/kg following LD with cy 1000 mg/m2 and flu 30 mg/m 2 3 days developed G3 CRS (DLT).No DLTs were reported in any other study arms.Conclusions: P-MUC1C-ALLO1 is an "off-the-shelf" allogeneic CAR-T with a manageable toxicity profile in heavily pre-treated solid tumor patients.Updated safety and efficacy data will be presented at the conference.
Authors
- Maurizio Mangolini (ORCID: https://orcid.org/0000-0002-0074-7935)
- Diana Pombal
- Sanvesh Srivastava (ORCID: https://orcid.org/0000-0002-5483-9579)
- Biao Ma (ORCID: https://orcid.org/0000-0002-6387-0957)
- Emily Souster
- Stanley Chukwudozie Onuoha (ORCID: https://orcid.org/0000-0002-6076-3910)
- Shaun Cordoba (ORCID: https://orcid.org/0009-0001-1519-3349)
- Kun Hu (ORCID: https://orcid.org/0009-0009-0378-4369)
- Yuhan Yang (ORCID: https://orcid.org/0000-0002-4177-6396)
- Lori Schultz
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100864
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00